Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination between Panacea Acquisition Corp. (a special purpose acquisition company) and Legacy Nuvation Bio Inc. on February 10, 2021. Following the merger, Legacy Nuvation Bio became a wholly-owned subsidiary, and Panacea changed its name to Nuvation Bio Inc. (the "Company"). The Company's Class A Common Stock and warrants began trading on the New York Stock Exchange under the symbols "NUVB" and "NUVB.WS," respectively, on January 11, 2021.
Key Financial Metrics and Capital Structure
The filing details significant capital raises and the resulting capital structure immediately following the closing of the business combination. Specific revenue, profit, or cash flow figures for the combined entity are not provided in this text, as historical financial data is incorporated by reference from the Proxy Statement/Prospectus.
- PIPE Investment: Purchasers acquired 47,655,000 shares of Class A Common Stock at $10.00 per share, totaling approximately $476.6 million.
- Forward Purchase: Certain purchasers acquired 2,500,000 shares of Class A Common Stock and 833,333 forward purchase warrants for an aggregate price of $25.0 million.
- Redemptions: Holders of 3,350 shares of Panacea Class A common stock exercised redemption rights for approximately $33,502.
- Outstanding Securities (Post-Closing):
- 216,650,055 shares of Class A Common Stock.
- 1,000,000 shares of Class B Common Stock (held by CEO David Hung, M.D.).
- 5,787,500 warrants exercisable at $11.50 per share.
- 9,571,976 shares of Class A Common Stock issuable upon exercise of exchanged options (weighted average exercise price of $4.41).
Material Changes and Corporate Actions
The primary material change is the completion of the merger, resulting in a change of control for Panacea and the public listing of Nuvation Bio. Key structural changes include:
- Exchange Ratio: Legacy Nuvation Bio common and preferred stock was converted into Company Class A Common Stock at an exchange ratio of approximately 0.196 shares per legacy share.
- Class B Stock: Legacy Class B stock was converted to Company Class B stock, which carries superior voting rights (election of directors) and a "sunset" provision converting to Class A if Dr. Hung's ownership falls below 43,188,000 shares or if he ceases to be CEO.
- Lock-Up Agreements: Approximately 71% of total outstanding shares are subject to lock-up agreements.
- Accountant Change: The Company engaged KPMG LLP as its independent registered public accounting firm, replacing WithumSmith+Brown, PC.
Guidance, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding the Company's strategy, future operations, and financial position. Management highlights several risks that could cause actual results to differ materially from expectations:
- Development Risks: Uncertainty regarding the initiation, timing, and results of preclinical studies and clinical trials for product candidates.
- Regulatory and Commercialization: Risks associated with obtaining regulatory approval and market acceptance of products.
- Financial Needs: The Company's ability to fund working capital requirements and the need for additional financing in the future.
- Third-Party Reliance: Dependence on third parties for clinical trials and manufacturing.
- Dividends: The Board does not anticipate declaring any dividends in the foreseeable future, intending to retain earnings for business operations.
Investor Verification Checklist
- Verify the total cash proceeds available to the Company post-closing, considering the $476.6 million PIPE, $25.0 million Forward Purchase, and the minimal redemption amount.
- Review the "Unaudited Pro Forma Condensed Combined Financial Information" in the Proxy Statement/Prospectus (referenced in the filing) to understand the combined entity's historical financial position.
- Confirm the specific terms of the Lock-Up Agreements covering 71% of outstanding shares to assess near-term liquidity constraints.
- Examine the "Sunset" provisions for Class B Common Stock to understand potential shifts in voting control regarding CEO David Hung, M.D.
- Review the "Risk Factors" section of the Proxy Statement/Prospectus for detailed disclosures on clinical trial timelines and regulatory hurdles.